Options

NOVO COMPLETES ACQUISITION OF STAKE IN GBM RESOURCES LIMITED AND BEGINS EVALUATING MALMSBURY PROJECT POTENTIAL

Monday, April 6, 2020 - 10:00pm

VANCOUVER, British Columbia, April 06, 2020 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (TSX-V: NVO; OTCQX: NSRPF) is pleased to announce that it has completed its subscription for 9,090,909 units (each a GBM Unit) of ASX-listed GBM Resources Limited (ASX: GBZ) (GBM).

Key Points: 
  • VANCOUVER, British Columbia, April 06, 2020 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (TSX-V: NVO; OTCQX: NSRPF) is pleased to announce that it has completed its subscription for 9,090,909 units (each a GBM Unit) of ASX-listed GBM Resources Limited (ASX: GBZ) (GBM).
  • Each GBM Unit is comprised of one ordinary share of GBM and one-half of one ordinary share purchase warrant (each a GBM Warrant).
  • Each of the 4,545,545 GBM Warrants entitles Novo to purchase one ordinary share of GBM at AUD $0.11 until April 6, 2023.
  • Following the issuance of the GBM Units, Novo owns approximately 4.13% of the issued and outstanding ordinary shares of GBM.

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Monday, April 6, 2020 - 9:15pm

The options were granted as inducement equity awards outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by each of the new employees.

Key Points: 
  • The options were granted as inducement equity awards outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by each of the new employees.
  • The options are subject to the terms and conditions of stock option agreements covering the respective grants and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and provides for the granting of stock options to new employees.
  • The stock option awards have an exercise price equal to the closing price of the Companys common stock on April 1, 2020.
  • GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, April 3, 2020 - 11:40pm

The equity awards were granted pursuant to the NASDAQ Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.

Key Points: 
  • The equity awards were granted pursuant to the NASDAQ Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.
  • The options have an exercise price equal to the closing price of Baudax Bios common stock as reported by NASDAQ on March 31, 2020.
  • The equity awards are subject to each individuals continued service with Baudax Bio through the applicable vesting dates.
  • Baudax Bio is a specialty pharmaceutical company focused on therapeutics for acute care settings.

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Friday, April 3, 2020 - 9:05pm

The stock option has an exercise price per share equal to $10.99, which was the closing trading price on April 1, 2020, the date of the grant.

Key Points: 
  • The stock option has an exercise price per share equal to $10.99, which was the closing trading price on April 1, 2020, the date of the grant.
  • The inducement award will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grant and 1/48th of the underlying shares vesting monthly thereafter over 36 months.
  • The stock option was granted pursuant to the Companys 2020 Employment Inducement Incentive Plan, which was approved by the Companys board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
  • For more information, please visit the Companys website at www.prothena.com and follow us on Twitter @ProthenaCorp.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, April 3, 2020 - 12:00pm

The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).
  • The options have an exercise price of$2.00 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

Radient Technologies Inc. Receives TSXV Approval to Extend Warrants

Thursday, April 2, 2020 - 10:30pm

The Warrants were originally issued pursuant to a private placement of units completed by the Company on October 14 , 2016.

Key Points: 
  • The Warrants were originally issued pursuant to a private placement of units completed by the Company on October 14 , 2016.
  • The Companys intention to seek extension of these warrants was previously announced on March 31, 2020.
  • Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products.
  • Forward-looking information includes, without limitation, statements regarding the extension of the term of the Warrants and the Companys future plans.

BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING

Thursday, April 2, 2020 - 2:00pm

For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.

Key Points: 
  • For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.
  • The offering is expected to close on or aboutApril 6, 2020, subject to customary closing conditions.
  • The gross proceeds to Bionano from this offering are expected to be approximately$18 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bionano, and excluding any proceeds that may be received upon exercise of the common warrants.
  • Such forward-looking statements include, without limitation, statements about Bionanos expectations regarding the completion, timing and size of the public offering and the anticipated use of net proceeds therefrom.

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, April 1, 2020 - 9:30pm

The stock options approved under the Inducement Grants were issued pursuant to Dicernas 2016 Inducement Plan and have an exercise price per share equal to $17.33, the fair market value on the grant date.

Key Points: 
  • The stock options approved under the Inducement Grants were issued pursuant to Dicernas 2016 Inducement Plan and have an exercise price per share equal to $17.33, the fair market value on the grant date.
  • The stock options have a 10-year term and are subject to the terms and conditions of the applicable stock option agreements.
  • The Company granted the stock options and RSUs as inducement materials to the new employees entering into employment with Dicerna Pharmaceuticals, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
  • This press release includes forward-looking statements pertaining to continued service of employees and future vesting of inducement grants.

REPAY Announces Extension of Expiration Date for the Consent Solicitation for Public Warrants

Wednesday, April 1, 2020 - 1:30pm

Repay Holdings Corporation (NASDAQ: RPAY) (the Company or REPAY) announced today that it has extended the expiration date for its previously announced consent solicitation from holders of its outstanding public warrants (CUSIP No.

Key Points: 
  • Repay Holdings Corporation (NASDAQ: RPAY) (the Company or REPAY) announced today that it has extended the expiration date for its previously announced consent solicitation from holders of its outstanding public warrants (CUSIP No.
  • The expiration date for the consent solicitation has been extended to 5:00 p.m., New York City time, on April 7, 2020 (such date and time, as the Company may further extend from time to time, the Expiration Date).
  • Except for the extended Expiration Date described above, the terms and conditions of the consent solicitation set forth in the Consent Solicitation Statement, dated March 24, 2020 (as it may be amended or supplemented from time to time, the Consent Solicitation Statement), and the accompanying Consent Form (together, the Consent Solicitation Documents), remain the same.
  • Holders of the Public Warrants are urged to review the Consent Solicitation Documents for the detailed terms of the consent solicitation and the procedures for consenting to the Proposed Amendments.

Radient Technologies Inc. Applies to Extend Warrants

Tuesday, March 31, 2020 - 10:30pm

EDMONTON, Alberta, March 31, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (Radient or the Company) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, has applied to the TSX Venture Exchange (the TSXV) to extend the term of 1,070,712 warrants originally scheduled to expire on April 14, 2020 (the Warrants) to April 14, 2021.

Key Points: 
  • EDMONTON, Alberta, March 31, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (Radient or the Company) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, has applied to the TSX Venture Exchange (the TSXV) to extend the term of 1,070,712 warrants originally scheduled to expire on April 14, 2020 (the Warrants) to April 14, 2021.
  • The Warrants were originally issued pursuant to a private placement of units completed by the Company on October 14, 2016.
  • The amendment to extend the expiry date of the Warrants to April 14, 2021 is subject to the approval of the TSXV.
  • Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products.